Our novel data highlight that different spectra of genetic mutations predict clinical outcome in U-CLL and M-CLL, respectively, with SF3B1 and XPO1 mutations being the most significant prognostic markers irrespective of subgroup assignment. This evidence concerns the gene XPO1 and B-cell chronic lymphocytic leukemia.